What is Ocular Therapeutix's revenue?

Ocular Therapeutix (OCUL) generated $52.0M in revenue over the trailing twelve months, down 12.8% year over year.

Is Ocular Therapeutix profitable?

Ocular Therapeutix is not currently profitable: it reported a net loss of $290.5M over the trailing twelve months, a -558.2% net margin.

What are Ocular Therapeutix's profit margins?

Gross margin is 87.2% and operating margin is -575.4%, with a -558.2% net margin.

What is Ocular Therapeutix's earnings per share?

Ocular Therapeutix's diluted EPS over the trailing twelve months is $-1.44.

Where does Ocular Therapeutix's income statement data come from?

Every line is extracted from Ocular Therapeutix's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Ocular Therapeutix OCUL Income Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Total revenue	$52.04M+0.2%	$51.95M-6.9%	$55.78M-1.6%	$56.66M-5.0%	$59.65M-6.4%
Total cost of revenue	$6.64M+1.0%	$6.57M+5.9%	$6.21M+3.6%	$6M+7.8%	$5.56M-1.1%
Gross profit	$45.4M0.0%	$45.38M-8.5%	$49.57M-2.2%	$50.67M-6.3%	$54.08M-6.9%
Gross margin	87.2%-0.1pp	87.3%-1.5pp	88.9%-0.5pp	89.4%-1.3pp	90.7%-0.5pp
Research and development	$220.45M+11.9%	$197.1M+5.2%	$187.29M+8.9%	$171.98M+14.8%	$149.76M+17.3%
Selling and marketing	$56.35M+4.5%	$53.92M+4.1%	$51.81M+5.1%	$49.29M+8.2%	$45.56M+9.5%
General and administrative	$68.03M+5.7%	$64.38M+5.0%	$61.32M+6.6%	$57.53M-8.5%	$62.85M+3.6%
Total costs & expenses	$351.48M+9.2%	$321.97M+5.0%	$306.62M+7.7%	$284.8M+8.0%	$263.73M+12.0%
Operating income	-$299.44M-10.9%	-$270.02M-7.6%	-$250.83M-10.0%	-$228.13M-11.8%	-$204.08M-18.8%
Operating margin	-575.4%-55.7pp	-519.8%-70.1pp	-449.7%-47.1pp	-402.6%-60.5pp	-342.2%-72.6pp
Interest expense	$11.63M-1.7%	$11.83M-2.3%	$12.11M-1.8%	$12.33M-1.4%	$12.51M-7.9%
Other income (expense), net	$8.94M+119%	$4.08M—	——	——	——
Net income	-$290.5M-9.2%	-$265.94M-6.5%	-$249.67M-15.2%	-$216.75M-12.5%	-$192.71M+0.4%
Net margin	-558.2%-46.3pp	-511.9%-64.3pp	-447.6%-65.1pp	-382.5%-59.4pp	-323.1%-19.4pp
Diluted earnings per share	-$1.44-1.4%	-$1.42+0.7%	-$1.43-12.6%	-$1.27-11.4%	-$1.14+8.8%
EBITDA	-$294.81M-11.0%	-$265.69M-7.7%	-$246.81M-10.1%	-$224.22M-12.0%	-$200.23M-19.2%
EBITDA margin	-566.5%-55.1pp	-511.4%-69.0pp	-442.4%-46.7pp	-395.7%-60.0pp	-335.7%-72.1pp
EBIT	-$299.44M-10.9%	-$270.02M-7.6%	-$250.83M-10.0%	-$228.13M-11.8%	-$204.08M-18.8%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Ocular Therapeutix.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Ocular Therapeutix's revenue?: Ocular Therapeutix (OCUL) generated $52.0M in revenue over the trailing twelve months, down 12.8% year over year.
Is Ocular Therapeutix profitable?: Ocular Therapeutix is not currently profitable: it reported a net loss of $290.5M over the trailing twelve months, a -558.2% net margin.
What are Ocular Therapeutix's profit margins?: Gross margin is 87.2% and operating margin is -575.4%, with a -558.2% net margin.
What is Ocular Therapeutix's earnings per share?: Ocular Therapeutix's diluted EPS over the trailing twelve months is $-1.44.
Where does Ocular Therapeutix's income statement data come from?: Every line is extracted from Ocular Therapeutix's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.